Therefore, the development of novel drugs that overcome gatekeeper mutation-induced acquired resistance to BCR-ABL inhibitors by CML cells is needed for the treatment of patients with CML. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.